BioSpace News Archive

DaVita Inc., announced that it will hold its quarterly conference call to discuss fourth quarter and full year results on Wednesday, February 22, 2023, at 5:00 p.m. Eastern Time.

Orbit Discovery Limited announced it has entered into a multi target Research Agreement with Endevica Bio Inc., a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in its Phase 1 trials.

IDEAYA Biosciences, Inc. announced its participation in the 2023 Guggenheim Oncology Conference.

Cerevel Therapeutics today announced it will report fourth quarter and full year 2022 financial results and business updates on Wednesday, February 22, 2023, before the U.S. financial markets open.

Leading health insurer and health care services company, Humana Inc . (NYSE: HUM) has hired health care industry veteran Sanjay Shetty, M.D., MBA, to lead its health care services business, CenterWell.

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational 1 basis and 7.1 percent on an organic 2 basis, all compared to the prior year period.

Nevro Corp. today announced that D. Keith Grossman , Nevro’s Chairman, CEO and President, and Rod MacLeod , Nevro’s CFO, will participate in a fireside chat at Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 at 8:45 am Eastern Time at Citigroup’s Corporate Headquarters in New York, NY.

Apyx Medical Corporation today announced it has submitted a 510(k) premarket notification (“510(k) submission”) for Renuvion APR Handpiece to the U.S. Food and Drug Administration (“FDA”), supported by a clinical study and real-world evidence.

Enveric Biosciences today announced that CEO Joseph Tucker, Ph.D., will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City.

Cybin Inc. is pleased to announce that it has received approval from an independent ethics committee in the Netherlands to initiate first-in-human dosing of its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule CYB004 through a protocol amendment to its ongoing CYB004-E Phase 1 trial.